Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin vs Pioglitazone in NAFLD
NCT05521633Phase 3Completed
- Sponsor
- King Edward Medical University
- Start
- Jun 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of liquid metformin (Aspargo Labs) and pioglitazone in non-alcoholic fatty liver disease (NAFLD), sponsored by King Edward Medical University. Primary endpoint: Liver transaminase levels at 6 months. Started Jun 2019; status: completed.
02
Drugs
liquid metformin (Aspargo Labs)pioglitazone
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT05521633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05521633.